Elizabeth Plimack, MD, MS, Talks Risk Categories in KEYNOTE-426 Trial on Advanced RCC
Elizabeth Plimack, MD, MS, discussed the analysis of risk categories for patients included in the KEYNOTYE-426 trial investigating axitinib and pembrolizumab over sunitinib for patients with advanced renal cell carcinoma.
Elizabeth Plimack, MD, MS, of the Fox Chase Cancer Center in Philadelphia, discussed the analysis of risk categories for patients when investigating axitinib (Inlyta) and pembrolizumab (Keytruda) over sunitinib (Sutent) in the updated analysis of KEYNOTE-426 presented at the 2020 ASCO Virtual Scientific Program.
Transcription:
One of the other analyses we did was look at risk categories: favorable risk vs poor and intermediate risk. In the poor and intermediate risk categories the benefit to overall survival, progression-free survival, and response rate remains and is highly statistically significant. In the favorable risk group, there was a benefit in terms of progression-free survival and response rate, but not overall survival. My commentary on that is that these patients do well. They are good risk or favorable risk. In this group of patients, it may just take longer for us to see any difference in overall survival since the vast majority are still alive, which is a good thing on this study.
Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors
A 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%.
Belzutifan Improves PFS Across Subgroups for Advanced ccRCC
July 12th 2024“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.
